This study is for patients currently on a stable dose of Wegovy (semaglutide) or Zepbound (tirzepatide). The study is evaluating the effectiveness of switching to a drug with monthly dosing to help lose or keep of the weight.
Status: Upcoming
Compensation: Up to $1,612
Location: Greenville - 545 Verdae Blvd., Lower Level, Suite B
Number of Visits: Discussed at screening
Age Group: 18+
Qualifications: Have taken Wegovy or Zepbound for at least 6 months and on the same dose for 3 months. Cannot be on a compounded medication. Experiencing a weight stability (plateau) for at least 6 weeks. BMI of 25 or greater.
Location(s):
Greenville - 545 Verdae Blvd., Lower Level, Suite B
*You may receive compensation for your time and completed study visits.